Powering the next generation of digital pathology labs.
Grade: D — Score: 25/100
AISight is a cloud-native, open platform that serves as an enterprise workflow solution for leading laboratories and research centers, enabling them to manage digital pathology workflows and integrate AI applications seamlessly. Its interoperability with major laboratory information systems (LIS) and scanner compatibility ensures that users can leverage existing infrastructure without disruption.
The platform is designed to be flexible and customizable, allowing laboratories to adapt workflows to various histopathology use cases. AISight's built-in image analysis and collaboration tools enhance user experience, making it pathologist-centric and intuitive.
Security and privacy are paramount, with AISight being ISO 27001 certified and adhering to recognized frameworks. The platform also supports a multi-partner AI portfolio, providing access to a wide range of AI algorithms that enhance diagnostic precision and lab efficiency.
AISight Image Management System: Not publicly disclosed; contact PathAI for pricing
Consider switching to Proscia: Proscia offers similar digital pathology solutions with a focus on scalability and integration.
No. PathAI states that AISight is for research use only in the United States and is not for use in diagnostic procedures. AISight Dx is a separate platform that PathAI says is FDA-cleared for primary diagnosis with specified scanner models, so that status should not be transferred to the core AISight product.
PathAI describes AISight as scanner-agnostic and interoperable with most major laboratory information systems and scanners, naming Hamamatsu, Leica, Roche and Philips. AISight Link supports LIS integration, but you should confirm the exact scanner model, interface, message flow and workflow in your own environment before contracting.
PathAI describes an onboarding process that covers planning, workflow and site configuration, scanner connections, LIS interfaces, integration build, end-to-end verification and staff training. The public onboarding guide does not establish a guaranteed implementation duration for every lab, so request a project plan with dependencies and acceptance criteria for your systems.
The AISight product page explicitly lists applications from Deep Bio, DoMore Diagnostics, Paige, and Visiopharm within its multi-partner portfolio. PathAI’s broader Digital Lab Solutions pages also feature MindPeak, Primaa, and Stratipath, but public partnership material ties these additional partners to AISight Dx and does not establish their availability in core AISight. Confirm the specific algorithm, product, region, intended use and commercial entitlement with PathAI.
PathAI describes an integrated AI portfolio, but the public AISight materials do not clearly specify which applications are bundled into a standard platform purchase and which, if any, require separate licensing or fees. Ask for a written quote that names each required application, its intended-use status, prerequisites and recurring or usage-based charges.
PathAI says Annotation Insights lets users draw a region of interest in the slide viewer and see results from supported AI algorithms, including quantitative outputs for selected tissue areas. Availability is tied to supported algorithms and workflows, and PathAI labels core AISight as research use only in the United States.
PathAI describes AISight as a cloud-native image-management platform with AISight Link and an integrated multi-partner AI portfolio. Proscia describes Concentriq as supporting more than 45 scanners, native bidirectional LIS and LIMS integrations, APIs and an SDK. These vendor descriptions are not a like-for-like compatibility guarantee, so compare your exact scanner and LIS configuration, required algorithms, regulatory scope, data terms, implementation plan and total quoted cost.
PathAI describes AISight as providing cloud-based image and data storage, but its public product page does not publish a calculable storage rate or complete pricing schedule. Ask the vendor to itemize the storage and archiving model, volume assumptions, retention period, backup handling, data retrieval or export charges, and any usage limits in the quote.
PathAI’s general Privacy Notice says its Platforms are operated and hosted from the United States and that protected health information is governed by applicable Customer Agreements, Terms of Use and Business Associate Agreements. The reviewed public pages do not provide an AISight-specific schedule for whole-slide images, related metadata, annotations and algorithm outputs, including retention, deletion, export, backups or whether those materials may be used for model training. Obtain the applicable agreements and written answers on these points before sending customer material.
No. PathAI states that AISight is for research use only in the United States, while AISight Dx has separate primary-diagnosis status in specified markets and with specified scanners; individual partner algorithms also have their own intended uses and regional status. Verify the label and authorization for each algorithm and intended workflow rather than assuming that platform access makes every application suitable for diagnosis.
How AI agents (ChatGPT, Perplexity, Claude, others) read this review page in the past 7 days. Updated weekly. View AISight AI Visibility Report.